Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

by Gray, Jhanelle E , Daniel, Davey , Quantin, Xavier , Reck, Martin , Ostoros, Gyula , Hui, Rina , Kubota, Kaoru , Cho, Byoung C , Villegas, Augusto , Spigel, David R , Antonia, Scott J , Taboada, Maria , de Wit, Maike , Tokito, Takaaki , Chiappori, Alberto , Kurata, Takayasu , Bourhaba, Maryam , Kim, Young-Chul , Paz-Ares, Luis , Mekhail, Tarek , de Castro Carpeño, Javier , Melillo, Giovanni , Planchard, David , Hiret, Sandrine , Wadsworth, Catherine , Faivre-Finn, Corinne , Vansteenkiste, Johan , Vicente, David , Dennis, Phillip A , Özgüroğlu, Mustafa , Lee, Ki H , Karapetis, Christos S , Murakami, Shuji

in Adult / Aged / Aged, 80 and over / Antibodies, Monoclonal - administration & dosage / Antibodies, Monoclonal - adverse effects / Antibodies, Monoclonal/administration & dosage/adverse effects / Antineoplastic Agents, Immunological - administration & dosage / Antineoplastic Agents, Immunological - adverse effects / Antineoplastic Agents, Immunological/administration & dosage/adverse effects / Body weight / Cancer / Cancer therapies / Carcinoma, Non-Small-Cell Lung - drug therapy / Carcinoma, Non-Small-Cell Lung - mortality / Carcinoma, Non-Small-Cell Lung - radiotherapy / Carcinoma, Non-Small-Cell Lung/drug therapy/mortality/radiotherapy / Chemoradiotherapy / Chemotherapy / Death / Disease control / Female / Human health and pathology / Human health sciences / Humans / Immunotherapy / Infusions, Intravenous / Intention to Treat Analysis / Kaplan-Meier Estimate / Life Sciences / Lung cancer / Lung Neoplasms - drug therapy / Lung Neoplasms - mortality / Lung Neoplasms - radiotherapy / Lung Neoplasms/drug therapy/mortality/radiotherapy / Male / Metastases / Metastasis / Middle Aged / Monoclonal antibodies / Non-small cell lung carcinoma / Oncologie / Oncology / Radiation therapy / Response rates / Sciences de la santé humaine / Smoking / Survival Rate / Targeted cancer therapy

2018

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

2018

Confirm

Do you wish to request the book?

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

2018

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Gray, Jhanelle E,

Daniel, Davey,

Quantin, Xavier,

Reck, Martin,

Ostoros, Gyula,

Hui, Rina,

Kubota, Kaoru,

Cho, Byoung C,

Villegas, Augusto,

Spigel, David R,

Antonia, Scott J,

Taboada, Maria,

de Wit, Maike,

Tokito, Takaaki,

Chiappori, Alberto,

Kurata, Takayasu,

Bourhaba, Maryam,

Kim, Young-Chul,

Paz-Ares, Luis,

Mekhail, Tarek,

de Castro Carpeño, Javier,

Melillo, Giovanni,

Planchard, David,

Hiret, Sandrine,

Wadsworth, Catherine,

Faivre-Finn, Corinne,

Vansteenkiste, Johan,

Vicente, David,

Dennis, Phillip A,

Özgüroğlu, Mustafa,

Lee, Ki H,

Karapetis, Christos S,

Murakami, Shuji

2018

Overview

In patients with locally advanced non–small-cell lung cancer who have undergone concurrent chemotherapy and radiation therapy, the use of durvalumab in the year after completing treatment significantly prolonged disease-free and overall survival as compared with placebo.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adult

/ Aged

/ Aged, 80 and over

/ Antibodies, Monoclonal - administration & dosage

/ Antibodies, Monoclonal - adverse effects

/ Antibodies, Monoclonal/administration & dosage/adverse effects

/ Antineoplastic Agents, Immunological - administration & dosage